1. Home
  2. Publications
  3. Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors

Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors

Bleicher I, Rossin E, Vavvas D. Reevaluating the Risk of Serious Adverse Events of Carbonic Anhydrase Inhibitors. JAMA Ophthalmol. 2022;140(7):745–746.
See also: Glaucoma, July 2022, All, 2022
Last updated on 03/06/2023